ERNA
Ernexa Therapeutics Inc.
Key Financials
Net Income
$-14084000
↑ 68.4%
Gross Profit
$486000
0.0%
Revenue
$582000
0.0%
Operating Income
$-9319000
↑ 40.5%
Total Assets
$5.8M
↑ 10.7%
EPS (Diluted)
$-2.24
↑ 31.3%
Total Liabilities
$3.4M
↓ 3.8%
Shareholders' Equity
$2.4M
↑ 41.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| DEF 14C | 4/13/2026 | View on SEC |
| PRE 14C | 4/1/2026 | View on SEC |
| EFFECT | 3/30/2026 | View on SEC |
| S-3/A | 3/24/2026 | View on SEC |
| 8-K | 3/20/2026 | View on SEC |
| S-3 | 3/16/2026 | View on SEC |
| 10-K | 3/13/2026 | View on SEC |
| 8-K | 2/26/2026 | View on SEC |
| SCHEDULE 13D/A | 2/17/2026 | View on SEC |
| 4 | 2/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ERNA |
| Company Name | Ernexa Therapeutics Inc. |
| CIK | 748592 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (617) 798-6700 |